Tremfya used for?

Tremfya is guselkumab, a monoclonal antibody that blocks IL-23. It’s approved to treat:

- Adults with moderate to severe plaque psoriasis
- Adults with active psoriatic arthritis

It is not approved for other conditions like eczema or non-psoriatic arthritis.

How it’s given: by subcutaneous injection. Typical dosing is 100 mg at week 0, week 4, then every 8 weeks thereafter (for both plaque psoriasis and psoriatic arthritis).

Safety notes (talk to your clinician about these):
- Risk of infections and TB reactivation; TB testing is usually done before starting.
- Monitor for allergic reactions or unusual infections.
- Vaccines: avoid live vaccines while on therapy; check with your doctor about other vaccines.

If you’d like, I can summarize benefits vs. risks for your specific situation or check dosing details.